• In the first quarter of 2026, PROCEPT BioRobotics reported revenue of US$83.13 million, up from US$69.16 million a year earlier, while its net loss widened to US$31.64 million and basic loss per share from continuing operations increased to US$0.56.
• Alongside this growth, the company reinforced the clinical and commercial appeal of its Aquablation therapy through stronger European guideline support, AI software clearance for its HYDROS system, and reaffirmed full-year 2026 revenue guidance.
• We’ll now explore how this combination of stronger Aquablation guideline support and reaffirmed 2026 revenue guidance influences PROCEPT BioRobotics’ investment narrative.

The future of work is here. Discover the 34 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.

PROCEPT BioRobotics Investment Narrative Recap

To own PROCEPT BioRobotics, you need to believe Aquablation can keep gaining surgeon and hospital adoption fast enough to justify ongoing losses and investment. The key short term catalyst is procedure and system growth supported by guideline endorsements and AI enhancements, while the biggest risk remains sustained operating losses if utilization and reimbursement do not keep pace. Q1 2026 results, with higher revenue but a wider net loss, do not materially change that risk reward balance yet.

The most relevant recent development is the European Association of Urology’s strong recommendation for Aquablation over TURP in men with moderate to severe BPH. This guideline upgrade directly supports the adoption and utilization catalyst that underpins PROCEPT’s reaffirmed 2026 revenue guidance and growing HYDROS install base, even as higher operating expenses keep the company in loss making territory.

Yet alongside these clinical wins, investors should be aware that persistent operating losses and rising costs could still...

PROCEPT BioRobotics' narrative projects $608.2 million revenue and $77.8 million earnings by 2029. This requires 23.6% yearly revenue growth and a $180.3 million earnings increase from -$102.5 million today.

Uncover how PROCEPT BioRobotics' forecasts yield a $30.44 fair value, a 24% upside to its current price.

Exploring Other Perspectives

The lowest estimate analysts take a much harsher view, assuming about 24.7% annual revenue growth and no profitability for at least three years, highlighting how differently you might weigh execution risk and reimbursement uncertainty after Q1 2026.

Explore 6 other fair value estimates on PROCEPT BioRobotics - why the stock might be worth over 2x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your PROCEPT BioRobotics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free PROCEPT BioRobotics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate PROCEPT BioRobotics' overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 13 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Invest in the nuclear renaissance through our list of 91 elite nuclear energy infrastructure plays powering the global AI revolution.
• This technology could replace computers: discover 26 stocks that are working to make quantum computing a reality.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.